menu search

AMGN / Could Amgen's Heart Disease Candidate Generate Billions in Sales?

Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Amgen recently shared positive clinical trial results for a heart disease drug candidate. Read More
Posted: Dec 11 2022, 09:15
Author Name: The Motley Fool
Views: 103115

AMGN News  

5 Dow stocks to track during the market correction

By MarketBeat
November 1, 2023

5 Dow stocks to track during the market correction

The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in eac more_horizontal

Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

By Market Watch
October 31, 2023

Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases. more_horizontal

U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara

By Reuters
October 31, 2023

U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara

The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara fo more_horizontal

Amgen's obesity drug plans, outlook for 2024

By Yahoo Finance
October 31, 2023

Amgen's obesity drug plans, outlook for 2024

Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acqu more_horizontal

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

By Zacks Investment Research
October 31, 2023

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guid more_horizontal

Amgen (AMGN) Q3 Earnings Top Estimates

By Zacks Investment Research
October 31, 2023

Amgen (AMGN) Q3 Earnings Top Estimates

Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings o more_horizontal

Amgen stock unmoved by earnings beat

By Proactive Investors
October 31, 2023

Amgen stock unmoved by earnings beat

In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings more_horizontal

Amgen's stock jumps premarket after earnings beat and company again raises guidance

By Market Watch
October 31, 2023

Amgen's stock jumps premarket after earnings beat and company again raises guidance

Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again r more_horizontal


Search within

Pages Search Results: